Pular para o conteúdo

EU Regulators Back Lilly's Foundayo Pill for Weight Loss and Type 2 Diabetes

22 de outubro de 2026 · 11 min

Notas do episódio

Europe's drug regulator has recommended approval of Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) for adults, covering both weight management and type 2 diabetes. The European Medicines Agency's human medicines committee (CHMP) adopted its positive opinion on October 15, 2026. In two weight-management studies of 4,740 adults, people taking Foundayo lost around 5% to 11% of their body weight at 72 weeks, depending on dose, compared with about 2% to 2.5% on placebo. In four type 2 diabetes studies of 3,765 adults, HbA1c fell by around 1.2 to 1.9 percentage points. The most common side effects were nausea, vomiting and diarrhoea. Unlike Novo Nordisk's Wegovy pill, which won EU approval in July for weight management only, Foundayo can be taken at any time of day with or without food. We cover what the committee looked at, what a CHMP opinion does and doesn't mean, how this fits the oral GLP-1 race between Lilly and Novo, and why the European Commission's final decision and country-by-country pricing and reimbursement still come next. Foundayo has been FDA-approved for weight management in the U.S. since April 2026. Sources: - European Medicines Agency news release (Oct 16, 2026): https://www.ema.europa.eu/en/news/new-oral-glp-1-medicine-weight-management-type-2-diabetes - EMA CHMP summary of positive opinion for Foundayo: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-foundayo_en.pdf - Fierce Pharma: https://www.fiercepharma.com/pharma/lillys-obesity-pill-revmeds-pancreatic-cancer-breakthrough-among-slew-chmp-endorsements - CNBC (Reuters): https://www.cnbc.com/2026/10/16/eli-lillys-weight-loss-pill-wins-eu-drug-regulators-backing.html - Pharmaceutical Executive: https://www.pharmexec.com/view/ema-panel-backs-lilly-foundayo-obesity-type-2-diabetes-europe Cover photo: European Medicines Agency headquarters, Amsterdam (photo © European Medicines Agency, cropped). This show is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication. More at glp1newspaper.com

Todos os episódios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News

Configurações

Exibição

Idioma

Define quais estações você vê primeiro na página inicial.

Histórico

As rádios e episódios ouvidos recentemente e suas últimas buscas ficam só neste navegador.

Avisos

Um aviso rápido quando um podcast que você segue tem um episódio novo. Desative podcasts individuais pelo sino na página deles.

Conta

Salve favoritos – no app e no site.

Atalhos de teclado

/
Abrir busca
Espaço
Reproduzir ou pausar
← →
No player: voltar 15 s, avançar 30 s (episódios) · na fileira: próximo bloco
↑ ↓
Na fileira: alvo dentro do bloco
Home / End
Na fileira: primeiro ou último bloco
Esc
Fechar janela ou menu
?
Esta visão geral
Tocando agora

Ir para a estação

A seguir

    Adicione episódios com “A seguir” – eles tocam depois do episódio atual.